Capricor Therapeutics' stock plummeted over 60% after FDA briefing documents for its Duchenne cell therapy, deramiocel, raised significant doubts about the data's effectiveness ahead of an advisory committee meeting. The FDA's stance suggests the single Phase 3 trial may not meet the standard for approval, leading to a sharp negative market reaction.
Capricor Therapeutics (CAPR) experienced a massive stock drop exceeding 60% after the FDA released briefing documents for its Duchenne cell therapy, deramiocel. The core issue is the FDA's indication that the data from the single pivotal Phase 3 trial (HOPE-3) may not meet the 'substantial evidence of effectiveness' standard typically requiring at least two well-controlled studies for approval. This pre-advisory committee meeting signal from the FDA is a significant blow, as it suggests a high likelihood of a negative recommendation or outright rejection, directly impacting the company's primary drug candidate. The short-term implication is extreme volatility and a sharp decline in CAPR's valuation, while the long-term outlook for deramiocel's approval now appears severely compromised, posing an existential risk to the company's pipeline and future revenue prospects.